NASDAQ · Biotechnology

Invivyd, Inc. (IVVD) Stock

$0.61 +0.54% NASDAQ: IVVD Healthcare

Valuation

MetricValue
Price$0.61
Market Cap$180.81M
P/E Ratio-2.08
P/B Ratio1.45
P/S Ratio4.15
EPS (TTM)$-0.30
52-Week High$3.07
52-Week Low$0.53
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-59.73%
ROA-49.04%
ROCE-59.90%
Gross Margin-105.66%
Operating Margin-105.66%
Net Margin-183.90%
Debt/Equity0.05
Current Ratio7.26

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$25.0M$53.0M
Operating Profit$-227.0M$-248.0M$-213.0M$-177.0M$-56.0M
Net Profit$-227.0M$-241.0M$-199.0M$-170.0M$-52.0M
EPS$-2.11$-2.17$-1.81$-1.43$-0.30
Op Margin———-696.8%-104.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$620.0M$383.0M$229.0M$130.0M$277.0M
Total Liabilities$62.0M$27.0M$52.0M$62.0M$35.0M
Cash$542.0M$92.0M$201.0M$69.0M$227.0M
Borrowings$0$4.0M$2.0M$1.0M$2.0M

Latest News

IVVD Stock Drops As PEMGARDA Loses Emergency Authorization In 2027 — Invivyd Eyes Full FDA Approval Stocktwits · Jul 6, 2026 Invivyd Gets FDA Notice of Pemgarda COVID-19 Emergency Use Authorization Termination MT Newswires · Jul 6, 2026 Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA GlobeNewswire · Jul 6, 2026 Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 2, 2026 NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer GlobeNewswire · Jun 29, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-185.0M$-220.0M$-173.0M$-170.0M$-58.0M
Investing Cash Flow$-51.0M$-232.0M$280.0M$0$0
Financing Cash Flow$-3.0M$0$0$-1.0M$0
Net Cash Flow$427.0M$-450.0M$109.0M$-131.0M$157.0M
Free Cash Flow$-185.0M$-222.0M$-174.0M$-171.0M$-58.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.03
EV / EBITDA-0.84
FCF Yield-45.28%
Quick Ratio5.86
Interest Coverage—
Return 1Y10.18%
Return 3Y-42.37%
Return 5Y—

Ownership

Insiders Held7.07%
Institutions Held83.97%
Institutions Float Held90.36%
Institutional HolderSharesReport Date
Janus Henderson Group PLC33,094,3302026-03-31
Perceptive Advisors Llc20,859,3032026-03-31
BVF Inc.19,525,0002026-03-31
Maverick Capital Ltd.18,970,9132026-03-31
Saturn V Capital Management LP10,949,0842026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CCCCC4 Therapeutics, Inc. $3.06 -3.77% -2.95 $376.46M 0.00%
CDXSCodexis, Inc. $1.28 -2.29% -4.05 $140.17M 0.00%
GNFTGenfit S.A. $8.95 +4.07% 261.07 $445.68M 0.00%
IMDXInsight Molecular Diagnostics Inc. $2.83 -0.35% -1.94 $92.61M 0.00%
NTHINeOnc Technologies Holdings, Inc. $3.27 +10.85% -1.20 $94.19M 0.00%

About Invivyd, Inc.

Invivyd, Inc. is led by CEO William E. Duke Jr., employs 99 people, headquartered in US, publicly traded since 2021.

Invivyd, Inc. (IVVD) stock trades at $0.61 with a market capitalization of $180.81M. The stock is valued at a negative price-to-earnings (P/E) ratio of -2.08, reflecting a net loss over the last twelve months, price-to-book of 1.45, price-to-sales of 4.15. Over the past 52 weeks the stock has ranged between $0.53 and $3.07, and currently trades 80.1% below its 52-week high.

On profitability, Invivyd, Inc. generates a return on equity (ROE) of -59.73% (negative, reflecting a net loss), return on capital employed of -59.90%, an operating margin of -105.66%, a net profit margin of -183.90%.

Invivyd, Inc. by the numbers, 2020–2025

Between 2020 and 2025 Invivyd, Inc. reported revenue of $0 rising to $53.0M. Compounded, revenue has grown —% a year over five years, —% over three, 112.0% over the last twelve months. Net profit rose to $-52.0M.

The most recent net margin is -183.90%. On a trailing twelve-month basis to Jun '26, revenue is $58.0M and net profit $-106.0M.

Borrowings stand at $2.0M, cash from operations was $-58.0M in the latest year, positive in 0 of the last 6.

Return on equity has averaged -98.5% over five years, and was -21.5% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Invivyd, Inc. (IVVD) — frequently asked questions

What is Invivyd, Inc. (IVVD) stock price today?

Invivyd, Inc. (IVVD) is currently trading at $0.61, up 0.54% today.

What is IVVD P/E ratio?

Invivyd, Inc.'s P/E ratio is -2.08. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is IVVD return on equity (ROE)?

Invivyd, Inc.'s return on equity (ROE) is -59.73%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is Invivyd, Inc.'s market cap?

Invivyd, Inc. has a market capitalization of $180.81M.

Does IVVD pay a dividend?

Invivyd, Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does IVVD carry?

Invivyd, Inc. has a debt-to-equity ratio of 0.05. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is IVVD's profit margin?

Invivyd, Inc. reports a net profit margin of -183.90% — the share of revenue left after every cost, including tax and interest.

What sector is IVVD in?

Invivyd, Inc. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is IVVD listed on?

Invivyd, Inc. trades on NASDAQ under the ticker IVVD.

What is IVVD's 52-week range?

Over the last year Invivyd, Inc. has traded between $0.53 and $3.07.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens IVVD currently matches

On the figures above, Invivyd, Inc. passes the filters for 4 of our ready-made screens, among them Penny Stocks, Stocks Under $5, Stocks Under $1. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Penny StocksStocks Under $5Stocks Under $1Micro Cap Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.